Reviewing TriSalus Life Sciences (NASDAQ:TLSI) and InspireMD (NYSE:NSPR)

InspireMD (NYSE:NSPR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Profitability

This table compares InspireMD and TriSalus Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-320.97%	-55.71%	-46.53%
TriSalus Life Sciences	N/A	N/A	-166.18%

Risk and Volatility

InspireMD has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Insider & Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 29.7% of InspireMD shares are owned by company insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for InspireMD and TriSalus Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	1	0	3.00
TriSalus Life Sciences	0	0	0	0	N/A

InspireMD presently has a consensus price target of $4.85, indicating a potential upside of 129.86%. Given InspireMD’s higher probable upside, equities research analysts plainly believe InspireMD is more favorable than TriSalus Life Sciences.

Valuation & Earnings

This table compares InspireMD and TriSalus Life Sciences’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$6.21 million	7.96	-$19.92 million	($1.08)	-1.95
TriSalus Life Sciences	$18.51 million	13.96	-$59.04 million	N/A	N/A

InspireMD has higher earnings, but lower revenue than TriSalus Life Sciences.

Summary

InspireMD beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.